ARRY Stock: Array Biopharma Inc Sentiment Improved in Q3 2017

0
143

Sentiment for Array Biopharma Inc (NASDAQ:ARRY)

Array Biopharma Inc (NASDAQ:ARRY) institutional sentiment increased to 1.21 in 2017 Q3. Its up 0.05, from 1.16 in 2017Q2. The ratio is better, as 93 investment managers increased and opened new holdings, while 77 sold and decreased their stakes in Array Biopharma Inc. The investment managers in our partner’s database now own: 190.80 million shares, up from 165.02 million shares in 2017Q2. Also, the number of investment managers holding Array Biopharma Inc in their top 10 holdings increased from 3 to 4 for an increase of 1. Sold All: 34 Reduced: 43 Increased: 52 New Position: 41.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.59 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

The stock increased 2.02% or $0.26 during the last trading session, reaching $13.14. About 2.22 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 176.51% since January 22, 2017 and is uptrending. It has outperformed by 159.81% the S&P500.

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on February, 8. They expect $-0.24 earnings per share, down 71.43 % or $0.10 from last year’s $-0.14 per share. After $-0.22 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 9.09 % negative EPS growth.

Redmile Group Llc holds 10.65% of its portfolio in Array BioPharma Inc. for 17.56 million shares. Bvf Inc Il owns 6.40 million shares or 10.01% of their US portfolio. Moreover, First Light Asset Management Llc has 5.72% invested in the company for 1.47 million shares. The California-based Venbio Select Advisor Llc has invested 5.11% in the stock. Ecor1 Capital Llc, a California-based fund reported 1.25 million shares.#img1#

Since January 1, 0001, it had 0 insider buys, and 6 selling transactions for $13.29 million activity.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Ratings analysis reveals 80% of Array BioPharma’s analysts are positive. Out of 10 Wall Street analysts rating Array BioPharma, 8 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $7 while the high is $18.0. The stock’s average target of $13.86 is 5.48% above today’s ($13.14) share price. ARRY was included in 29 notes of analysts from June 3, 2016. The firm earned “Buy” rating on Tuesday, October 31 by Cowen & Co. Piper Jaffray maintained it with “Buy” rating and $18.0 target in Wednesday, September 20 report. As per Monday, January 30, the company rating was downgraded by Leerink Swann. Piper Jaffray maintained the stock with “Overweight” rating in Monday, September 26 report. The firm has “Buy” rating given on Friday, June 3 by Suntrust Robinson. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Tuesday, October 31 by Stifel Nicolaus. On Thursday, July 13 the stock rating was maintained by Jefferies with “Buy”. Piper Jaffray maintained Array BioPharma Inc. (NASDAQ:ARRY) on Wednesday, November 29 with “Buy” rating. The firm has “Buy” rating by SunTrust given on Friday, June 3. Leerink Swann maintained the shares of ARRY in report on Monday, September 26 with “Outperform” rating.

More notable recent Array BioPharma Inc. (NASDAQ:ARRY) news were published by: Bizwest.com which released: “Array BioPharma launches spinoff to develop drugs for rare diseases” on December 27, 2017, also Prnewswire.com with their article: “Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month …” published on January 20, 2018, Prnewswire.com published: “Lifshitz & Miller LLP Announces Investigation of Alteryx, Inc., Array …” on December 28, 2017. More interesting news about Array BioPharma Inc. (NASDAQ:ARRY) were released by: Prnewswire.com and their article: “Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results …” published on January 16, 2018 as well as Streetinsider.com‘s news article titled: “Array Biopharma (ARRY) Reports Updated Results for Phase 3 BEACON CRC Trial …” with publication date: January 22, 2018.

LEAVE A REPLY

Please enter your comment!
Please enter your name here